Volume 6.14 | Apr 17

Mammary Cell News 6.14 April 17, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Mammary Morphogenesis and Regeneration Require the Inhibition of EMT at Terminal End Buds by Ovol2 Transcriptional Repressor
Scientists showed that restricting the epithelial-to-mesenchymal transition (EMT) of mammary epithelial cells by transcription factor Ovol2 is required for proper morphogenesis and regeneration. Deletion of Ovol2 blocks mammary ductal morphogenesis, depletes stem and progenitor cell reservoirs, and leads epithelial cells to undergo EMT in vivo to become nonepithelial cell types. [Dev Cell] Abstract | Graphical Abstract
mTeSR1: Most Published Feeder-Free hPSC Maintenance Medium. Click to View Top Applications
PUBLICATIONS (Ranked by impact factor of the journal)

Tumor Microenvironment-Based Feed-Forward Regulation of NOS2 in Breast Cancer Progression
Scientists showed that up-regulation of nitric oxide synthase (NOS2) occurs in response to hypoxia, serum withdrawal, IFN-γ, and exogenous nitric oxide (NO), consistent with a feed-forward regulation of NO production by the tumor microenvironment in breast cancer biology. [Proc Natl Acad Sci USA] Abstract | Full Article

Essential Role for TrpC5-Containing Extracellular Vesicles in Breast Cancer with Chemotherapeutic Resistance
In adriamycin-resistant human breast cancer cells (MCF-7/ADM), investigators analyzed the role of transient receptor potential channel 5 (TrpC5) in extracellular vesicles formation and transfer as well as the diagnostic implications. [Proc Natl Acad Sci USA] Abstract

Mechanistic Elucidation of the Antitumor Properties of Withaferin A in Breast Cancer
Scientists defined activation of extracellular signal-regulated kinase-ribosomal S6 kinase and ETS-like transcription factor 1-CHOP (C-EBP homologous protein) kinase pathways in upregulating transcription of the death receptor 5 (DR5). Through this route, withaferin A acted as an effective DR5 activator capable of potentiating the biologic effects of celecoxib, etoposide, and TRAIL. [Cancer Res] Abstract

The Sodium Channel β1 Subunit Mediates Outgrowth of Neurite-Like Processes on Breast Cancer Cells and Promotes Tumor Growth and Metastasis
Researchers found that SCN1B mRNA/β1 protein were up-regulated in breast cancer (BCa) specimens, compared with normal breast tissue. β1 up-regulation substantially increased tumor growth and metastasis in a xenograft model of BCa. [Int J Cancer] Abstract | Full Article

Retinoic Acid Reduces Migration of Human Breast Cancer Cells: Role of Retinoic Acid Receptor Beta
Administration of retinoic acid (RA) in breast cancer cells induced retinoic acid receptor β (RARβ) gene expression that was greatest after 72 hours with a concentration 1 μM. High concentrations of RA increased the expression of RARβ causing an inhibition of the 60% in cell migration and significantly decreased the expression of migration-related proteins. [J Cell Mol Med] Full Article

Bisphenol AF-Induced Endogenous Transcription Is Mediated by ERα and ERK1/2 Activation in Human Breast Cancer Cells
The authors investigated the effect and mechanism of bisphenol AF (BPAF)-induced endogenous transcription detected by real-time PCR in human breast cancer cells. They found that BPAF stimulated transcription of estrogen responsive genes, such as trefoil factor 1, growth regulation by estrogen in breast cancer 1 and cathepsin D, through dose-dependent and time-dependent manners in T47D and MCF7 cells. [PLoS One]
Full Article


Phase IIa Trial of Trastuzumab Emtansine with Pertuzumab for Patients with Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer
This Phase IIa study characterized the safety and efficacy of two human epidermal growth factor receptor 2 (HER2)-targeted agents, trastuzumab emtansine and pertuzumab, in patients with HER2-positive metastatic breast cancer. [J Clin Oncol] Abstract

Randomized Phase II Study of Weekly Paclitaxel with and without Carboplatin followed by Cyclophosphamide/Epirubicin/5-Fluorouracil as Neoadjuvant Chemotherapy for Stage II/IIIA Breast Cancer without HER2 Overexpression
Addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer may improve pathological complete response rates. Investigators evaluated the efficacy and safety of carboplatin and weekly paclitaxel followed by cyclophosphamide, epirubicin, and 5-fluorouracil as neoadjuvant chemotherapy for HER2-negative breast cancer. [Breast Cancer Res Treat] Abstract

See Who's Published: Leading Breast Cancer Researchers Use MammoCult
Breast Cancer Stem Cells: Multiple Capacities in Tumor Metastasis
The authors focus on recently identified key factors, including the breast cancer stem cells (BCSCs) among circulating tumor cells, interaction of BCSCs with the host, epithelial mesenchymal transition, tumor microenvironment, the intrinsic resistance due to HER2 expression, potential biomarkers of BCSCs and cancer cell immune signaling. [Cancer Lett] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Komen Chicago Awards Nearly $1.3 Million to Local Organizations to Fight Breast Cancer
Susan G. Komen® – Chicago announced its 2014 class of grantees. The total award of nearly $1.3 million will be allocated across the 17 recipient organizations. In addition, Komen also awarded grants to fund the development of new programs at Mercy Hospital and Medical Center and at Recovery on Water. [Chicagoland Area Affiliate of Susan G. Komen®] Press Release

Grants Will Support Research on Lung and Breast Cancer by Early-Career Scientists
Grants totaling $100,000 from Friends of the Comprehensive Cancer Center will bolster innovative research by two UT Southwestern Medical Center scientists who are at an early stage in their careers, but already are doing promising work on potential targets for lung and breast cancer. [University of Texas Southwestern Medical Center] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd Annual World Orphan Drug Congress Asia
June 10-14, 2014
Singapore, Singapore

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Biological Markers and Novel Targets for Aggressive Breast and Prostate Cancer (University of Bergen)

PhD Position – Breast Cancer Translational Research Laboratory (Jules Bordet Institute)

Postdoctoral Position in Stem Cell and Cancer (Harvard Medical School)

MSc & PhD Positions – Cell Biology, Neurobiology, Neuroimmunology, Cancer Biology, Computational Biology (Hanyang University)

Postdoctoral Research Associate – Extracellular Microenvironment in Cancer (Institute of Translational Medicine, University of Liverpool)

Junior Faculty Position – Breast Pathology (Northwestern University)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us